{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-06T18:27:19.145901+00:00","company":{"ticker":"ACRS","cik":1557746,"company_name":"Aclaris Therapeutics, Inc."},"pagination":{"limit":100,"returned":16,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"shareholder_vote","fact_key":"4e1815388bb364a975c23501acfcf98467a7746c","cik":1557746,"ticker":"ACRS","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2026-06-04T20:01:13+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-04","outcome":"passed","proposal_text":"Ratification of the selection of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2026","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"17,146","votes_against":"159,714","votes_for":"112,322,811","votes_withheld":null}]},"claim":"Aclaris Therapeutics, Inc. shareholders approved Ratification of the selection of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-04 meeting.","evidence_excerpt":"The stockholders ratified the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-070494","anchor_url":"https://secwatch.observer/filing/0001104659-26-070494#claim-4e1815388bb364a975c23501acfcf98467a7746c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1557746/000110465926070494/0001104659-26-070494-index.htm"},{"fact_type":"shareholder_vote","fact_key":"9be26db0e2d3a17ea4b3d3ff01fbd0e586d214fe","cik":1557746,"ticker":"ACRS","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2026-06-04T20:01:13+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-04","outcome":"passed","proposal_text":"Advisory approval of the compensation of the Company’s named executive officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"19,360,478","subject":null,"votes_abstain":"34,378","votes_against":"9,734,691","votes_for":"83,370,124","votes_withheld":null}]},"claim":"Aclaris Therapeutics, Inc. shareholders approved Advisory approval of the compensation of the Company’s named executive officers at the 2026-06-04 meeting.","evidence_excerpt":"The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-070494","anchor_url":"https://secwatch.observer/filing/0001104659-26-070494#claim-9be26db0e2d3a17ea4b3d3ff01fbd0e586d214fe","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1557746/000110465926070494/0001104659-26-070494-index.htm"},{"fact_type":"shareholder_vote","fact_key":"d947360ab21306dec3b75422193466ac4c35fa88","cik":1557746,"ticker":"ACRS","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2026-06-04T20:01:13+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-04","outcome":"passed","proposal_text":"Election of two nominees to serve as directors until the 2029 annual meeting","proposal_type":"director_election","results":[{"broker_non_votes":"19,360,478","subject":"Anand Mehra, M.D.","votes_abstain":null,"votes_against":null,"votes_for":"83,063,569","votes_withheld":"10,075,624"},{"broker_non_votes":"19,360,478","subject":"Maxine Gowen, Ph.D.","votes_abstain":null,"votes_against":null,"votes_for":"84,209,108","votes_withheld":"8,930,085"}]},"claim":"Aclaris Therapeutics, Inc. shareholders approved Election of two nominees to serve as directors until the 2029 annual meeting at the 2026-06-04 meeting.","evidence_excerpt":"The stockholders elected two nominees to serve as directors on the Board of Directors until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-070494","anchor_url":"https://secwatch.observer/filing/0001104659-26-070494#claim-d947360ab21306dec3b75422193466ac4c35fa88","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1557746/000110465926070494/0001104659-26-070494-index.htm"},{"fact_type":"earnings_release","fact_key":"003a75826e5f4f17666aa65b746a53b1770358fa","cik":1557746,"ticker":"ACRS","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2026-05-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss was $19.8 million","period_text":"first quarter of 2026","report_date":"2026-05-07","result_type":"reported_results","revenue_text":"$2.0 million"},"claim":"Aclaris Therapeutics, Inc. reported first quarter of 2026 results: revenue $2.0 million, net income Net loss was $19.8 million.","evidence_excerpt":"First quarter 2026 Net loss was $19.8 million for the first quarter of 2026 compared to $15.1 million for the first quarter of 2025. Total revenue was $2.0 million for the first quarter of 2026 compared to $1.5 million for the first quarter of 2025.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-056669","anchor_url":"https://secwatch.observer/filing/0001104659-26-056669#claim-003a75826e5f4f17666aa65b746a53b1770358fa","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1557746/000110465926056669/0001104659-26-056669-index.htm"},{"fact_type":"governance_change","fact_key":"d5cb05491e7022b56cf3e7fcff3b9f8b7e10eb2c","cik":1557746,"ticker":"ACRS","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2025-06-05T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-06-05","item_codes_triggered":["5.03"],"summary_text":"Increased authorized common stock from 200,000,000 to 400,000,000 shares"},"claim":"Aclaris Therapeutics, Inc.: Increased authorized common stock from 200,000,000 to 400,000,000 shares (effective 2025-06-05).","evidence_excerpt":"the stockholders of the Company approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 200,000,000 shares to 400,000,000 shares","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001558370-25-008430","anchor_url":"https://secwatch.observer/filing/0001558370-25-008430#claim-d5cb05491e7022b56cf3e7fcff3b9f8b7e10eb2c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1557746/000155837025008430/0001558370-25-008430-index.htm"},{"fact_type":"executive_change","fact_key":"b9d36fefb3","cik":1557746,"ticker":"ACRS","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2024-11-18T23:59:59+00:00","payload":{"action":"will no longer serve role","action_category":"role_change","departure_tone":"routine","effective_date":"2024-11-18","interim":false,"role":"President","role_category":"president","successor_name":"Hugh Davis","successor_named":true},"claim":"Neal Walker changed role as President at Aclaris Therapeutics, Inc..","evidence_excerpt":"In connection with Dr. Davis’s appointment, Neal Walker will no longer serve as the Company’s President but will continue to serve as the Company’s Interim Chief Executive Officer.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001558370-24-015838","anchor_url":"https://secwatch.observer/filing/0001558370-24-015838#claim-b9d36fefb3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1557746/000155837024015838/0001558370-24-015838-index.htm"},{"fact_type":"executive_change","fact_key":"3ee71f1906","cik":1557746,"ticker":"ACRS","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2024-11-18T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-11-18","interim":false,"role":"Class III Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Hugh Davis was appointed as Class III Director at Aclaris Therapeutics, Inc..","evidence_excerpt":"The Board also appointed Dr. Davis to the Board, effective November 18, 2024, to serve as a Class III director","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-24-015838","anchor_url":"https://secwatch.observer/filing/0001558370-24-015838#claim-3ee71f1906","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1557746/000155837024015838/0001558370-24-015838-index.htm"},{"fact_type":"executive_change","fact_key":"ebb34a570d","cik":1557746,"ticker":"ACRS","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2024-11-18T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-11-18","interim":false,"role":"President and Chief Operating Officer","role_category":"coo","successor_name":null,"successor_named":false},"claim":"Hugh Davis was appointed as President and Chief Operating Officer at Aclaris Therapeutics, Inc..","evidence_excerpt":"On November 16, 2024, the board of directors (the “ Board ”) of the Company appointed Hugh Davis, Ph.D., as the Company’s President and Chief Operating Officer effective November 18, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-24-015838","anchor_url":"https://secwatch.observer/filing/0001558370-24-015838#claim-ebb34a570d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1557746/000155837024015838/0001558370-24-015838-index.htm"},{"fact_type":"earnings_release","fact_key":"0ac64782dd907214dd2a83720be8b6da6cc35579","cik":1557746,"ticker":"ACRS","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2024-05-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss was $16.9 million","period_text":"first quarter of 2024","report_date":"2024-05-07","result_type":"reported_results","revenue_text":"$2.4 million"},"claim":"Aclaris Therapeutics, Inc. reported first quarter of 2024 results: revenue $2.4 million, net income Net loss was $16.9 million.","evidence_excerpt":"​ Financial Results First Quarter 2024 ● Net loss was $16.9 million for the first quarter of 2024 compared to $28.2 million for the first quarter of 2023. ● Total revenue was $2.4 million for the first quarter of 2024 compared to $2.5 million for the first quarter of 2023. The decrease was primarily driven by lower contract research revenue during the three months","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001558370-24-007055","anchor_url":"https://secwatch.observer/filing/0001558370-24-007055#claim-0ac64782dd907214dd2a83720be8b6da6cc35579","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1557746/000155837024007055/0001558370-24-007055-index.htm"},{"fact_type":"executive_change","fact_key":"af923c3ea8","cik":1557746,"ticker":"ACRS","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2024-03-19T23:59:59+00:00","payload":{"action":"not stand for re-election","action_category":"departure","departure_tone":"routine","effective_date":"2024-06-06","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Bryan Reasons departed as Director at Aclaris Therapeutics, Inc..","evidence_excerpt":"Also on March 14, 2024, Bryan Reasons, a member of the Board, notified the Company that he will not stand for re-election as a director of the Company upon the expiration of his current term, which expires at the Annual Meeting.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-24-003572","anchor_url":"https://secwatch.observer/filing/0001558370-24-003572#claim-af923c3ea8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1557746/000155837024003572/0001558370-24-003572-index.htm"},{"fact_type":"executive_change","fact_key":"8354fb7007","cik":1557746,"ticker":"ACRS","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2024-03-19T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-06-06","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Andrew Powell resigned as Director at Aclaris Therapeutics, Inc..","evidence_excerpt":"On March 14, 2024, Andrew Powell, a member of the board of directors (the “ Board ”) of Aclaris Therapeutics, Inc. (the “ Company ”), notified the Company of his intent to resign as a member of the Board, effective as of the date of the Company’s 2024 Annual Meeting of Stockholders, which is expected to be held on June 6, 2024 (the “ Annual Meeting ”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-24-003572","anchor_url":"https://secwatch.observer/filing/0001558370-24-003572#claim-8354fb7007","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1557746/000155837024003572/0001558370-24-003572-index.htm"},{"fact_type":"earnings_release","fact_key":"3856431e5b33f2e935fe859e7a204aab60eaaf6e","cik":1557746,"ticker":"ACRS","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2024-02-27T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss was $1.5 million for the fourth quarter of 2023 compared to $27.6 million for the fourth quarter of 2022. ... N","period_text":"fourth quarter and full year ended December 31, 2023","report_date":"2024-02-27","result_type":"reported_results","revenue_text":"Total revenue was $17.6 million for the fourth quarter of 2023 compared to $7.8 million for the fourth quarter of 2022."},"claim":"Aclaris Therapeutics, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue Total revenue was $17.6 million for the fourth quarter of 2023 compared to $7.8 million for the fourth quarter of 2022., net income Net loss was $1.5 million for the fourth quarter of 2023 compared to $27.6 million for the fourth quarter of 2022. ... N.","evidence_excerpt":"Aclaris Therapeutics, Inc. (the “ Registrant ”) issued a press release announcing its financial results for the quarter and full year ended December 31, 2023","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-24-001752","anchor_url":"https://secwatch.observer/filing/0001558370-24-001752#claim-3856431e5b33f2e935fe859e7a204aab60eaaf6e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1557746/000155837024001752/0001558370-24-001752-index.htm"},{"fact_type":"executive_change","fact_key":"3c01a83b3a","cik":1557746,"ticker":"ACRS","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2024-02-05T23:59:59+00:00","payload":{"action":"departed","action_category":"departure","departure_tone":"not_disclosed","effective_date":null,"interim":false,"role":"Chief Executive Officer and President","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Douglas Manion departed as Chief Executive Officer and President at Aclaris Therapeutics, Inc..","evidence_excerpt":"On February 4, 2024, in connection with Douglas Manion’s departure from the Company as the Company’s Chief Executive Officer and President, the Company and Dr. Manion entered into a Separation Agreement","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-24-000769","anchor_url":"https://secwatch.observer/filing/0001558370-24-000769#claim-3c01a83b3a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1557746/000155837024000769/0001558370-24-000769-index.htm"},{"fact_type":"executive_change","fact_key":"92b8bea230","cik":1557746,"ticker":"ACRS","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2024-02-05T23:59:59+00:00","payload":{"action":"terminated","action_category":"departure","departure_tone":"termination","effective_date":"2024-01-31","interim":false,"role":"Chief Medical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Gail Cawkwell was terminated as Chief Medical Officer at Aclaris Therapeutics, Inc..","evidence_excerpt":"On January 31, 2024, Aclaris Therapeutics, Inc. (the “ Company ”) terminated the employment of Gail Cawkwell, M.D., PhD., the Company's Chief Medical Officer, without cause, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-24-000769","anchor_url":"https://secwatch.observer/filing/0001558370-24-000769#claim-92b8bea230","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1557746/000155837024000769/0001558370-24-000769-index.htm"},{"fact_type":"executive_change","fact_key":"25f37a6499","cik":1557746,"ticker":"ACRS","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2024-02-05T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-01-17","interim":true,"role":"Interim Chief Executive Officer and President","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Neal Walker was appointed as Interim Chief Executive Officer and President at Aclaris Therapeutics, Inc..","evidence_excerpt":"in connection with the departure of Dr. Manion, on January 15, 2024, the Board appointed Neal Walker as the Company’s Interim Chief Executive Officer and President, effective January 17, 2024.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001558370-24-000770","anchor_url":"https://secwatch.observer/filing/0001558370-24-000770#claim-25f37a6499","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1557746/000155837024000770/0001558370-24-000770-index.htm"},{"fact_type":"executive_change","fact_key":"49c51ba7f8","cik":1557746,"ticker":"ACRS","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2024-02-05T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-01-16","interim":false,"role":"Chief Executive Officer and President","role_category":"ceo","successor_name":"Neal Walker","successor_named":true},"claim":"Douglas Manion resigned as Chief Executive Officer and President at Aclaris Therapeutics, Inc..","evidence_excerpt":"On January 15, 2024, the Company and Douglas Manion mutually agreed that Dr. Manion will step down as the Company’s Chief Executive Officer and President and resign from the Board of Directors (the “ Board ”), effective January 16, 2024.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001558370-24-000770","anchor_url":"https://secwatch.observer/filing/0001558370-24-000770#claim-49c51ba7f8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1557746/000155837024000770/0001558370-24-000770-index.htm"}]}